HIGHLIGHTS
- who: Bennet Y. Weber et al. from the melweis University, Budapest have published the article: Rosiglitazone Does Not Show Major Hidden Cardiotoxicity in Models of Ischemia/Reperfusion but Abolishes Ischemic Preconditioning-Induced Antiarrhythmic Effects in Rats In Vivo, in the Journal: Pharmaceuticals 2022, 15, 1055. of 20/02/2022
- what: The authors aimed to investigate the hidden cardiotoxicity of in_(I/R) injury models. This is the first demonstration that chronic administration of rosiglitazone does not show major hidden cardiotoxic effects in models of myocardial I/R injury. The authors focused on the chronically changed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.